A prospective clinical study to determine efficacy and feasibility of a brief course or standard course of anthracycline-based chemotherapy and consolidation radiation therapy in non-Hodgkin's lymphoma patients over 60 years of age.
Methods
Twenty-five consecutive patients with stage I-IE intermediate to high-grade non-Hodgkin's lymphoma aged 60 and older were treated in an outpatient setting in the Radiotherapy Oncology and Hematology units. All patients had a performance status of 0-1 according to WHO criteria. The survival end points, ie, overall survival, disease-free survival and event-free survival, were considered. Lactate dehydrogenase value, nodal versus extranodal localization and dose intensity were assessed as risk factors for disease-free and overall survival. A comparison using logrank analysis with a wellmatched group of stage I-IE non-Hodgkin's lymphoma patients aged less than 60 years was performed.
Results
The 5-year overall and disease-free survival rates were 90% and 86%, respectively. There was no statistical difference with respect to the younger population regarding these survival end points. Finally, the 5-year event-free survival was 85% and 86% for elderly and younger patients, respectively, without statistical difference (P = 0.41). Neither acute nor late toxicity (G3-G4) was observed during chemotherapy and radiotherapy treatment and the follow-up in the elderly group.
Conclusions
We confirm the efficacy and feasibility of a full-dose combined chemoradiotherapy in elderly patients with a good performance status with localized I-IE intermediate to high-grade non-Hodgkin's lymphoma.
CoiffierB.: What treatment for elderly patients with aggressive lymphoma?Ann Oncol, 5: 873–875, 1994.
3.
GomezH., HidalgoM., CasanovaL., ColomerR., Lee Kay PenD., OteroJ., RodriguezW., CarracedoC., Cortes-FunesH., VallejosC.: Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol, 16: 2065–2069, 1998.
4.
ArmitageJ.O., PotterJ.F.: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications with advancing age. J Am Geriatr Soc, 32: 269–273, 1984.
5.
VoseJ.M., ArmitageO., WeisenburgerP.J.B., BiermanP.J., SorensenS., HutchinsM., MoravecD.F., HoweD., DowlingM.D., MaillardJ.: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol, 6: 1838–1844, 1988.
6.
SalminenE.K.: The outcome of 70-year-old non-Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys, 32: 349–353, 1995.
7.
OguchiM., IzunoI., TakeiK., ShikamaN., SasakiS., GomiK., SoneS.: Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys, 37: 87–92, 1997.
8.
WylieJ.P., CowanR.A., DeakinD.P.: The role of radiotherapy in the treatment of localized intermediate and high-grade non-Hodgkin's lymphoma in elderly patients. Radiother Oncol, 49: 9–14, 1998.
9.
SweetD.L., KinzieJ., GaekeM.E.: Survival of patients with localized diffuse histiocytic lymphoma. Blood, 58: 1218–1223, 1981.
10.
KaminskiM.S., ColemanC.N., ColbyT.V.: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med, 104: 747–756, 1986.
11.
ConnorsJ.M., KlimoP., FaireyR.N., VossN.: Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med, 107: 25–30, 1987.
12.
LongoD.L., GlatsteinE., DuffeyP.I., IhdeD.C., HubbardS.M., FisherR.I., JaffeE.S., GilliomM., YoungR.C., DeVitaV.T.: Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol, 1: 1295–1302, 1989.
13.
TondiniC., ZaniniM., LombardiF., BengalaC., RoccaA., GiardiniR., BuzzoniR., ValagussaP., BonadonnaG.: Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II istologically aggressive non-Hodgkin's lymphomas. J Clin Oncol, 11: 720–725, 1993.
14.
MillerT.P., DahlbergS., CassadyJ.R.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med, 339: 2126–2133, 1998.
15.
HarrisL., JaffeE.S., SteinH., BanksP.M., ChanJ.K.C., ClearyM.L., DelsolG., De Wolf-PeetersC., FaliniB., GatterK.C., GroganT.M., IsaacsonP.G., KnowlesD.M., MasonD.Y., Muller-HermelinkH.K., PileriS.A., PirisM.A., RalfiakaerE., WarnkeR.A.: A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood, 84: 1361–1392, 1994.
16.
CarboneP.P., KaplanH.S., MusshofK.: Report of the committee on Hodgkin's disease staging classification. Cancer Res, 31: 1860–1861, 1971.
17.
BruceD., HorningS.J., CoiffierB., ShippM.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17: 1244–1253, 1999.
18.
HryniukW.M., GoodyearM.: The calculation of received dose intensity. J Clin Oncol, 8: 1935–1937, 1990.
19.
International Commission on Radiation Units and Measurements:Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). ICRU Report 62, 1999.
20.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations:J Am Stat Assoc, 53: 457–481, 1958.
21.
CoxD.R.: Regression models and life tables (with discussion). J R Statist Soc (b), 34: 187–220, 1972.
22.
TirelliU., ErranteD., Van GlabbekeM., TeodorovicI., Kluin-NelemansJ.C., ThomasJ., BronD., RostiG., SomersR., ZagonelV., NoordijkE.M.: CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol, 16: 27–34, 1998.
23.
FicherR.I., GaynorE.R., DahlbergS.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med, 328: 1002–1006, 1993.
24.
BastionY., BlayJ.Y., DivineM., BriceP., BordessouleD., SebbanC., BlancM., TillyH., LederlinP., DeconinckE., SallesB., DumontetC., BriereJ., CoiffierB.: Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival. A groupe d'etude des lymphomes de l'adulte study on 453 patients older than 69 years. J Clin Oncol, 15: 2945–2953, 1997.
25.
KamathS.S., MarcusR.B., LynchJ.W., MendenhallN.P.: The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 44: 563–568, 1999.
26.
ConnorsJ.M., KlimoP., FaireyR.N.: Brief chemotherapy and involved field radiation therapy for limited stage, histologically aggressive lymphoma. Ann Intern Med, 107: 25–30, 1987.
27.
KrolA.D.G., BerenschotH.W.A., DoekharanD., Henzen-LogmansS., van der HoltB., van't VeerM.B.: Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high-grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol, 58: 251–255, 2001.
28.
FonsecaR., HabermannT.M., ColganJ.P., O'NeilB., WhiteW.L., WitzigT.E., EganK.S., MartensonJ.A., BugartL.J., InwardsD.J.: Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer, 88: 154–161, 2000.
29.
MartelliM., GuglielmiC., ColuzziS., AvvisatiG., AmadoriS., GiovanniniM., TorromeoC., MandelliF.: P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol, 11: 2362–2369, 1993.
